• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Rader Chris P was granted 700 shares (SEC Form 4)

    5/13/25 6:39:12 PM ET
    $HBCP
    Banks
    Finance
    Get the next $HBCP alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    RADER CHRIS P

    (Last) (First) (Middle)
    C/O HOME BANCORP, INC.
    503 KALISTE SALOOM ROAD

    (Street)
    LAFAYETTE LA 70508

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HOME BANCORP, INC. [ HBCP ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/12/2025 A 700 A (1) 16,611.7163 D(2)(3)(4)(5)
    Common Stock 8,428.711 I By IRA
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes the grant of 700 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2026 and that may be settled only in shares of the Issuer's common stock.
    2. Includes the grant of 550 restricted stock units pursuant to the Issuer's 2014 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2022 and that may be settled only in shares of the Issuer's common stock.
    3. Includes the grant of 600 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2023 and that may be settled only in shares of the Issuer's common stock.
    4. Includes the grant of 600 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2024 and that may be settled only in shares of the Issuer's common stock.
    5. Includes the grant of 600 restricted stock units pursuant to the Issuer's 2021 Incentive Plan that vest in equal installments at the rate of 20% per year commencing on May 12, 2025 and that may be settled only in shares of the Issuer's common stock.
    /s/ Chris P. Rader 05/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HBCP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBCP

    DatePrice TargetRatingAnalyst
    4/24/2025$48.50 → $51.50Market Perform
    Hovde Group
    2/21/2025$60.00Overweight
    Piper Sandler
    11/12/2024$53.00 → $54.50Outperform → Market Perform
    Hovde Group
    10/21/2024$48.50 → $53.00Outperform
    Hovde Group
    10/21/2024$50.00Mkt Perform → Outperform
    Raymond James
    7/19/2024$45.00 → $48.50Outperform
    Hovde Group
    1/24/2024$40.00 → $43.00Overweight → Neutral
    Piper Sandler
    3/20/2023Mkt Perform
    Raymond James
    More analyst ratings